Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.
Dangoor, Adam Beech, Janette Sherlock, David J Lee, Siow Ming Scarffe, J Howard Swindell, Ric Ranson, Malcolm R
Dangoor, Adam
Beech, Janette
Sherlock, David J
Lee, Siow Ming
Scarffe, J Howard
Swindell, Ric
Ranson, Malcolm R
Citations
Altmetric:
Abstract
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
Description
Date
2005-02-28
Publisher
Collections
Keywords
Liver Cancer
Type
Article
Citation
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. 2005, 92 (4):628-30 Br. J. Cancer